Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

June 27, 2025

ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at the US Hereditary Angioedema Association's 2025 National Summit to be held from July 10-13, 2025, in Baltimore, Maryland.

Details of the presentations are as follows:

- **Title:** Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study
  Presenter: Michael E. Manning, M.D.
  Format: Poster Presentation, #22
  Date, time: Friday, July 11, 12:30-13:30 ET
- **Title:** Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study
  Presenter: Michael E. Manning, M.D.
  Format: Poster Presentation, #20
  Date, time: Friday, July 11, 12:30-13:30 ET
- **Title:** CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
  Presenter: H. Henry Li, M.D., Ph.D.
  Format: Poster Presentation, #5
  Date, time: Friday, July 11, 12:30-13:30 ET
- **Title:** Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
  Presenter: Marc A. Riedl, M.D., M.S.
  Format: Poster Presentation, #23
  Date, time: Friday, July 11, 12:30-13:30 ET
- **Title:** Durability of response to a single dose of oral deucrictibant for on-demand treatment of hereditary angioedema attacks
  Presenter: Joshua S. Jacobs, M.D.
  Format: Poster Presentation, #9
  Date, time: Friday, July 11, 12:30-13:30 ET
- **Title:** Deucrictibant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched Analysis
  Presenter: Mark D. Scarupa, M.D.
  Format: Poster Presentation, #7
  Date, time: Friday, July 11, 12:30-13:30 ET

The posters will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: https://ir.pharvaris.com/news-events/events-presentations.

About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of oral therapies to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit https://pharvaris.com/.

Contact
Maggie Beller
Executive Director, Head of Corporate and Investor Communications
maggie.beller@pharvaris.com